TEV-48574 is in clinical development as a potential treatment for ulcerative colitis (UC) and Crohn's disease (CD); and has been shown to reduce fibrosis, inflammation, and mortality in animal models of IBD and asthma.1 The main objectives of this phase 1 study were to characterize the ...
Herein, we describe the phase 2b basket trial evaluating TEV-48574 in UC and CD (clinicaltrials.gov NCT05499130), currently ongoing along with a long-term extension study (LTE)(NCT05668013). METHODS. In this double-blind placebo-controlled global study, TEV-48574 or placebo is administered ...